RT Journal Article
SR Electronic
T1 BrainXcan identifies brain features associated with behavioral and psychiatric traits using large scale genetic and imaging data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.01.21258159
DO 10.1101/2021.06.01.21258159
A1 Liang, Yanyu
A1 Melia, Owen
A1 Caroll, Timothy J.
A1 Brettin, Thomas
A1 Brown, Andrew
A1 Im, Hae Kyung
YR 2022
UL http://medrxiv.org/content/early/2022/02/02/2021.06.01.21258159.abstract
AB Advances in brain MRI have enabled many discoveries in neuroscience. Comparison of brain MRI features between cases and controls have highlighted potential causes of psychiatric and behavioral disorders (complex traits). However, due to the cost of collecting MRI data and the difficulty in recruiting particular patient groups, most studies have small sample sizes, limiting their reliability. Furthermore, reverse causality complicates interpretation because many observed brain differences are the result rather than the cause of the disease. Here we propose a method (BrainXcan) that leverages the power of large-scale genome-wide association studies (GWAS) and reference brain MRI data to discover new mechanisms of disease etiology and validate existing ones. BrainXcan tests the association with genetic predictors of brain MRI-derived features and complex traits to pinpoint relevant region-specific and cross-brain features. As this approach requires only genetic data, BrainXcan allows us to test a host of hypotheses on mental illness, across many disorders and MRI modalities, using existing public data resources. For example, our method shows that reduced axonal density across the brain is associated with the risk of schizophrenia, consistent with the disconnectivity hypothesis. We also find structural features in the hippocampus, amygdala, and anterior cingulate cortex, among others associated with schizophrenia risk highlighting the potential of our approach, which uses orthogonal lines of evidence to inform the biology of complex traits.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYL, OM, and HKI received partial funding from P30DK020595, U01HG009086.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our study was determined to be nonhuman subject but the University of Chicago's IRB.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available in https://github.com/hakyimlab/brainxcan and links therein